Cas Endonucleases Specificity Efficiency Genetic Editing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRISPR-Cas systems for nucleic acid editing face challenges in specificity, efficiency, and adaptability to diverse target nucleic acid molecules, limiting their effectiveness in genetic editing and disease treatment.
Innovation Solution
Development of novel Cas endonucleases with varying amino acid sequences and properties, including fusion proteins and conjugates with heterologous moieties, to enhance specificity, efficiency, and adaptability in nucleic acid editing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional CRISPR-Cas systems are used for nucleic acid editing, then the basic editing function is achieved, but the specificity and efficiency are limited
Solution Approach 1:
The patent modifies amino acid sequences of Cas endonucleases to create variants with improved specificity and efficiency. By changing specific parameters (amino acid composition, sequence identity thresholds of 80-99%), the enzyme's binding affinity and cleavage precision are optimized without losing fundamental catalytic function.
Solution Approach 2:
The patent creates fusion proteins by combining Cas endonuclease domains with heterologous moieties. This composite approach integrates multiple functional elements into a single molecule, enhancing both specificity through improved target recognition and efficiency through coordinated catalytic activity.
2Adaptability or versatility
If traditional CRISPR-Cas systems are used, then simple structure is maintained, but adaptability to diverse target nucleic acid molecules is limited
Solution Approach 1:
The patent develops Cas endonuclease variants that can recognize and bind to diverse PAM sequences and target structures. By engineering universal recognition capabilities across different Cas protein families (Type V, VI, VIII), a single system can adapt to multiple target nucleic acid molecules without requiring complete system redesign.
Solution Approach 2:
The patent introduces flexible linker regions and modular domain architectures that allow the Cas endonucleases to dynamically adjust their conformation when binding to different target sequences. This structural flexibility enables adaptation to diverse targets while maintaining a relatively simple core enzyme structure.
3Manufacturing precision
If Cas endonucleases with higher specificity are developed, then editing precision is improved, but the complexity of protein engineering increases
Solution Approach 1:
The patent divides the Cas endonuclease into functional domains (REC lobe, NUC lobe, PAM recognition domain) and independently optimizes each segment for specific functions. This modular approach allows precise engineering of binding interfaces without redesigning the entire protein, reducing overall engineering complexity while improving editing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel Cas endonucleases demonstrate improved efficiency and specificity in editing nucleic acid molecules, enabling more precise and effective genetic modifications and disease treatments.
Implementation Method 1
the crRNA directs the Cas endonuclease to a target nucleic acid molecule, and the Cas endonuclease mediates cleavage of the target nucleic acid molecule
Data Source
AI summary
Provided herein are Cas endonucleases (and functional fragments, functional variants, and domains thereof), nucleic acid molecules encoding the same, and systems comprising the same. The disclosure further relates to methods of utilizing the Cas endonucleases (or nucleic acid molecules encoding the same), including, e.g., in methods of editing a nucleic acid molecule (e.g., a gene) and methods of treating diseases (e.g., genetic diseases).